---
title: "Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Clinical evidence"
description: "Formulary evidence on Tovecimig (CTX-009, ABL001) in Second-line advanced biliary tract cancer: Clinical evidence. Covers COMPANION-002; ABL001-P1bC phase 1b/2 study of CTX-009 with irinotecan or paclitaxel; COMPANION-003; 2024-0279 first-line CTX-009 with gemcitabine, cisplatin, and durvalumab; Tovecimig plus FOLFIRI in second line metastatic colorectal cancer; CTX-009 with or without CTX-471 for recurrent glioblastoma; 1 further heading. 170 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/clinical-evidence"
published: "2026-09-21T22:15:09-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 COMPANION-002

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Registered purpose of the trial

> “This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.”

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.1-2"></a>

###### Objective stated in the trial design publication

> “COMPANION-002 is a multicenter, randomized, phase II/III study evaluating the efficacy and safety of CTX-009 in combination with paclitaxel as second-line treatment for patients with advanced or metastatic BTC.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.1.1-3"></a>

###### Sponsor-stated purpose and regulatory intent

> “Tovecimig (CTX-009), our bispecific antibody targeting DLL4 and VEGF-A, is currently being evaluated in a randomized Phase 2/3 trial in the United States in combination with paclitaxel in patients with biliary tract cancer (“BTC”) who received one prior treatment regimen.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status: registry record

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2023-01-09” |
| Primary completion (estimated) | “2027-08-31” |
| Study completion (estimated) | “2027-08-31” |
| Enrollment (actual) | “168” |
| Recruitment status | “Active, not recruiting” |
| Last update posted | “2026-09-02” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.2-2"></a>

###### Registered sites

> “This study has 34 locations”
> “United States”

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.2-3"></a>

###### Planned site count in the trial design publication

> “The planned sample size is approximately 150 patients. This is a multicenter study with 32 study sites.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.1.2-4"></a>

###### Completion of enrollment

> “The trial was fully enrolled in August 2024 with 168 patients randomized in a 2:1 ratio to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57).”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-3.1.1.2-5"></a>

###### Data cut-off dates of the reported analyses

> “Data cutoff from COMPANION - 002 as of March 2025.”
> “Data cutoff from COMPANION - 002 as of April 2026.”

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Registered design details

| Design feature | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Single (Outcomes Assessor)” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.3-2"></a>

###### Blinded independent central review of the primary endpoint

> “A blinded independent review committee will be used to assess the primary study endpoint.”

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.3-3"></a>

###### Randomization ratio and stratification factors

> “Patients are randomized to a 2:1 ratio, and crossover is allowed to the experimental arm at the time of progression in the control arm for patients that continue to meet eligibility criteria. Stratification factors include stage (locally advanced vs metastatic), anatomic subtype of the primary tumor (intrahepatic cholangiocarcinoma vs other) and ECOG performance status (0 or 1).”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.1.3-4"></a>

###### Crossover from the control arm

> “Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.”

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

> “Patients in the paclitaxel-only arm who progressed could cross over to the tovecimig plus paclitaxel arm after centrally confirmed progression if they also still met the enrollment criteria for the study.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.3-5"></a>

###### Regulatory origin of the randomized design

> “Based on the efficacy data and following discussions with the FDA, while the trial had met the criteria to advance to Part 2, FDA recommended and we agreed to forego the second stage of the study and advance tovecimig directly to a randomized Phase 2/3 study in patients with BTC treated in the second-line setting.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-3.1.1.3-6"></a>

###### Independent safety monitoring

> “An independent Data Monitoring Committee (DMC) has reviewed safety data at four separate (pre-specified) DMC meetings and, after each meeting, recommended continuation of the study without modification.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria: registry record

| Criterion | Quoted registry text |
| --- | --- |
| Age | “18 years of age or older” |
| Diagnosis | “Histologically or cytologically confirmed unresectable advanced, metastatic, or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma)” |
| Prior therapy | “Patients must have radiologically documented progression after a prior gemcitabine and platinum containing chemotherapy regimen as first line therapy for locally advanced unresectable or metastatic disease.” |
| Measurable disease | “At least one lesion measurable as defined by RECIST v1.1” |
| Performance status | “Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1” |
| Life expectancy | “Predicted life expectancy of at least 12 weeks” |
| Hepatic function | “Total bilirubin ≤ 1.5 X ULN” |
| Renal function | “Estimated creatinine clearance ≥ 30 mL/min based on Cockcroft-Gault” |
| Proteinuria | “Urine protein ≤ 1+ by Dipstick (Only when urinalysis shows a protein dipstick result of > 1 positive (+), the total protein volume (<1.0 g/24hr) can be confirmed with a 24-hour urine test.)” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion of participants eligible for an approved targeted therapy

> “Patients who are eligible to be treated with a molecularly targeted therapy on a labelled regimen after receiving first-line chemotherapy. Patients who received a molecularly targeted therapy as part of their first line treatment may be eligible, as determined by the Sponsor Medical Monitor.”

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.4-3"></a>

###### Cardiovascular, hemorrhagic, and gastrointestinal exclusions relevant to angiogenesis inhibition

> “Congestive heart failure (CHF) that corresponds to Class II or a higher class under New York Heart Association (NYHA) classification, or less than 50% of left ventricular ejection fraction (LVEF)”
> “Uncontrolled hypertension (SBP/DBP >140/90 mmHg) (e.g., patient with SBP/DBP >140/90 mmHg despite the best care including optimizing the anti-hypertensive medication regimen)”
> “Patients with any history of hypertensive crisis or pre-existing hypertensive encephalopathy”
> “Active hemorrhage, hemorrhagic diathesis, coagulopathy or tumor in great arteries”
> “History of clinically significant gastroenterological disease, such as peptic ulcer, GI bleeding, GI or non-GI fistula, perforation, abdominal abscess, clinical symptoms, and signs of GI obstruction, need for parenteral hydration or nutrition, or inflammatory bowel disease (IBD)”
> “Pre-existing hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 28 days prior to screening”
> “Patients with percutaneous transhepatic biliary drains (PTBD)”

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Dosing of both arms as reported by the sponsor

> “All patients were dosed with 80 mg/m2 of paclitaxel on days 1, 8 and 15 of every 28-day cycle. Patients in the tovecimig arm were also dosed with 10 mg/kg of tovecimig on days 1 and 15 of each 28-day cycle.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.5-2"></a>

###### Registered intervention schedule

| Intervention | Registry description |
| --- | --- |
| CTX-009 | “IV infusion on day 1 and 14 of every 28 day cycle” |
| Paclitaxel | “IV infusion on day 1, 8, and 15 of every 28 day cycle” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.5-3"></a>

###### Adverse event grading and safety follow-up

> “Safety will be monitored throughout the study and for 30 days after the end of treatment. Adverse events will be assessed as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Registered primary outcome measure

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Best Overall Response” | “Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1” | “From randomization to treatment discontinuation for any reason, average 6 months” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.6.1-2"></a>

###### Registered secondary outcome measures

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Progression Free Survival” | “Time from randomization until the date of objective PD (as assessed by RECIST 1.1) or the date of death (by any cause in the absence of disease progression)” | “From randomization to first documented objective PD or death if PD does not occur, average 6 months” |
| “Duration of Response” | “The time between the date of the radiological evaluation that first confirmed CR or PR and the date of the radiation evaluation that first confirmed Progressive Disease (PD)” | “From first confirmed CR or PR to confirmed PD, average 6 months” |
| “Overall Survival” | “Time from randomization until the date of death by any cause. Patients who are still alive at the time of the analysis, or who have become lost to follow-up or withdrawn consent will be censored at their last date known to be alive” | “From randomization to death from any cause, average 12 months” |
| “Disease Control Rate” | “Percentage of patients whose BOR is assessed as CR, PR, or Stable Disease (SD)” | “From randomization to treatment discontinuation for any reason, average 6 months” |
| “Incidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities” | “Incidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities for all randomized patients who received at least one dose of study treatment (either CTX-009 or paclitaxel)” | “From randomization to 60 days after the last dose of study treatment, average 7 months” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-3.1.1.6.1-3"></a>

###### Endpoint definitions in the trial design publication, including the quality-of-life instrument

> “The primary end point is ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by independent central review (ICR). The secondary end points are progression free survival, duration of response, overall survival, disease control rate, safety and quality of life measured with EORTC QLQ-C30.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.1.6.1-4"></a>

###### Response-rate signal from the preceding phase 2 study that motivated the endpoint

> “In a phase II study of patients with advanced biliary tract cancer who had received one or two prior therapies, CTX-009 with paclitaxel demonstrated a 37.5% overall response rate (ORR).”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.1.6.1-5"></a>

###### Low response rate of available second-line regimens against which the endpoint was sized

> “For the approximately 85% of patients with BTC whose tumors do not harbor an actionable mutation with an approved targeted therapy, there is currently no FDA-approved treatment in the second line setting. The combinations of therapeutics used in this setting, which are not labeled for this indication, generally have an ORR of ~5% or less and patients face a median overall survival of approximately six months.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned and randomized sample size

> “The planned sample size is approximately 150 patients. This is a multicenter study with 32 study sites.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

> “The study enrolled 168 adult patients, randomized in a 2:1 ratio to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.7.1-2"></a>

###### Power and treatment-effect assumption

> “This study was designed to detect a 23% absolute difference in response rate between the two arms, with 90% power and a two-sided alpha of 0.05.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.1.7.1-3"></a>

###### Event threshold triggering the time-to-event analyses

> “The trial requires a threshold of events in 80% of patients to trigger the secondary endpoint analyses.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

> “In the Phase 2/3 trial, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; therefore, the analyses of progression-free survival (PFS) and OS are expected to be reported in April 2026.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Populations analyzed for efficacy and for safety

| Analysis set | Tovecimig plus paclitaxel | Paclitaxel |
| --- | --- | --- |
| Intent-to-treat population, efficacy analyses | “n=111” | “n=57” |
| Population reported for treatment-emergent adverse events | “n=108” | “n=53” |

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="topic-3.1.1.7.2-2"></a>

###### Crossover-adjusted overall survival analysis and its assumptions

> “In the rank-preserving structural failure time (RPSFT) OS analysis, the combination also had a median OS of 8.9 months compared to 9.4 months for paclitaxel alone (HR=1.13, p=0.65). Though the RPSFT analysis is intended to adjust for crossover, its validity depends on certain assumptions that were not met in this study and thus its results here are largely uninterpretable.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.7.2-3"></a>

###### Prespecified status of the crossover analyses

> “An additional, pre-specified secondary endpoint analyzed PFS in the patients in the paclitaxel arm who crossed over to receive tovecimig plus paclitaxel.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

> “Although this was a prespecified analysis, statistical assumptions for the RPSFT were not met.”

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Crossover from the control arm and total exposure to tovecimig

> “Tovecimig did not meet the OS secondary endpoint due to high crossover from the control arm (31 of 57 patients, or 54%) and prolonged survival of those crossover patients after receiving tovecimig, as further described below. As a result of this crossover, 85% (142 of 168) of patients in the study received tovecimig plus paclitaxel with a pooled OS in the study of 8.9 months.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.8.1-2"></a>

###### Participants not evaluable for response

> “Not Evaluable: patients who did not receive a Week-8 scan.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="topic-3.1.1.8.1-3"></a>

###### Treatment discontinuation, withdrawal, and follow-up counts

> “Between April 2023 and August 2024, 210 patients were screened and 168 randomized to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). In total, 108 and 53 patients, respectively, received treatment”
> “Thirty-one (31) patients (54.4%) in the paclitaxel arm crossed over and received tovecimig plus paclitaxel. Overall, 84.5% (n=142/168) of patients received tovecimig plus paclitaxel.”
> “Overall, 66 (39.3%) patients received subsequent therapy after study completion, of which 60.6% received a fluorouracil-based regimen.”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Balance of baseline characteristics between arms

> “Baseline characteristics were well balanced”

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="topic-3.1.1.8.2-2"></a>

###### Baseline demographics and disease characteristics, n (%) unless stated

| Characteristic | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
| --- | --- | --- |
| Median age, years | “65.0” | “63.0” |
| Male | “53 (47.7)” | “24 (42.1)” |
| Female | “58 (52.3)” | “33 (57.9)” |
| Asian | “17 (15.3)” | “10 (17.5)” |
| White | “84 (75.7)” | “40 (70.2)” |
| African American | “4 (3.6)” | “6 (10.5)” |
| Unknown or other race | “6 (5.4)” | “1 (1.8)” |
| Intrahepatic primary location | “62 (55.9)” | “30 (52.6)” |
| Other primary location (extrahepatic, gallbladder, ampullary) | “49 (44.1)” | “27 (47.4)” |
| ECOG performance status 0 | “53 (47.7)” | “27 (47.4)” |
| ECOG performance status 1 | “58 (52.3)” | “30 (52.6)” |
| Locally advanced disease | “12 (10.8)” | “5 (8.8)” |
| Metastatic disease | “99 (89.2)” | “52 (91.2)” |

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: objective response rate as first reported

> “17.1% ORR for tovecimig in combination with paclitaxel (19 of 111 patients) including one complete response, compared to 5.3% for paclitaxel alone (3 of 57 patients), in patients with BTC in the second line setting”
> “This 11.8% relative improvement in ORR for those receiving the combination was statistically significant (p=0.031).”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="topic-3.1.1.8.3-2"></a>

###### Primary endpoint: objective response rate in the final analysis

> “In the final data analysis, the overall response rate (ORR), the primary endpoint in the study, improved to 18.0% (20/111 patients) in the tovecimig combination arm from a previously reported 17.1%.”
> “With this change, the p-value improved to 0.0228 compared to paclitaxel alone (ORR of 5.3% in the paclitaxel arm).”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="topic-3.1.1.8.3-3"></a>

###### Primary and key secondary endpoints in the peer-reviewed publication

> “168 patients were randomized 2:1 to tovecimig+paclitaxel (n=111) or paclitaxel alone (n=57). Tovecimig+paclitaxel significantly improved BICR-assessed ORR (18.0% vs 5.3%; P=.0228) and PFS (4.7 vs 2.6 months; hazard ratio [HR], 0.44; P<.0001).”
> “Overall, 142 patients (85%) received tovecimig; no difference in OS was observed (HR, 1.05; P=.779).”
> “Tovecimig combined with paclitaxel significantly improved ORR and PFS versus paclitaxel alone as second-line therapy for patients with BTC.”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-3.1.1.8.3-4"></a>

###### Progression-free and overall survival with confidence intervals in the peer-reviewed publication

> “Median BICR-assessed PFS was 4.7 months (95% CI, 3.9–5.6) with tovecimig plus paclitaxel versus 2.6 months (95% CI, 1.9–3.6) with paclitaxel alone, corresponding to a 56% reduction in the risk of progression or death”
> “Median OS was 8.9 months (95% CI, 7.0–11.2)”
> “with tovecimig plus paclitaxel versus 9.4 months (95% CI, 6.5–13.5) in patients randomized to paclitaxel alone”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-3.1.1.8.3-5"></a>

###### Crossover-adjusted overall survival by two-stage estimation

> “A post-hoc exploratory analysis of OS to correct for crossover using the Two-Stage Estimation revealed an HR of 0.85 (95% CI, 0.59–1.26”
> “This method estimates the treatment effect on OS if crossover had not occurred.”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-3.1.1.8.3-6"></a>

###### Prespecified intrahepatic cholangiocarcinoma subgroup

> “In the subgroup of patients with intrahepatic cholangiocarcinoma, defined according to a prespecified anatomic subsite stratification factor, treatment effects were consistent with those observed in the overall ITT population, with an ORR of 15.3% versus 0%”
> “median PFS of 5.1 months versus 3.0 months (HR, 0.32; 95% CI, 0.18–0.57”
> “the study was not powered to evaluate efficacy within individual anatomical or molecular subgroups.”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-3.1.1.8.3-7"></a>

###### Best overall response by blinded independent central review, intent-to-treat population

| Best overall response | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
| --- | --- | --- |
| Overall response rate (complete plus partial response) | “19 (17.1%)” | “3 (5.3%)” |
| Complete response | “1 (0.9%)” | “0 (0.0%)” |
| Partial response | “18 (16.2%)” | “3 (5.3%)” |
| Stable disease | “49 (44.1%)” | “19 (33.3%)” |
| Non-complete response / non-progressive disease | “9 (8.1%)” | “2 (3.5%)” |
| Progressive disease | “18 (16.2%)” | “24 (42.1%)” |
| Not evaluable | “16 (14.4%)” | “9 (15.8%)” |

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="topic-3.1.1.8.3-8"></a>

###### Central confirmation of responses

> “The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="topic-3.1.1.8.3-9"></a>

###### Key secondary endpoint: progression-free survival

> “Tovecimig in combination with paclitaxel demonstrated a statistically significant improvement in median PFS of 4.7 months compared to 2.6 months for paclitaxel alone (HR=0.44, p<0.0001). Progression was confirmed in each case by BICR.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.8.3-10"></a>

###### Key secondary endpoint: overall survival in the intent-to-treat population

> “In the ITT OS analysis, tovecimig in combination with paclitaxel had a median OS of 8.9 months compared to 9.4 months for the control arm, which included 26 patients (46%) who received paclitaxel alone and 31 patients (54%) who crossed over to receive tovecimig in combination with paclitaxel (HR=1.05, p=0.78).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.8.3-11"></a>

###### Efficacy summary with hazard ratios and two-sided p values

| Endpoint | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) | Hazard ratio | Two-sided p value |
| --- | --- | --- | --- | --- |
| Overall response rate | “19 (17.1%)” | “3 (5.3%)” | Not reported | “p=0.031” |
| Progression-free survival, months | “4.7” | “2.6” | “0.44” | “p<0.0001” |
| Overall survival, intent-to-treat, months | “8.9” | “9.4” | “1.05” | “p=0.78” |
| Overall survival, crossover-adjusted by rank-preserving structural failure time, months | “8.9” | “9.4” | “1.13” | “p=0.65” |

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="topic-3.1.1.8.3-12"></a>

###### Prespecified secondary analysis of progression-free survival before and after crossover

> “In this analysis, the pre-crossover PFS (PFS1) on paclitaxel alone was compared to PFS with tovecimig post-crossover (PFS2) in the same crossover patients (n=31). In this subset, tovecimig demonstrated a statistically significant improvement with median PFS2 of 3.5 months after treatment with tovecimig compared to median PFS1 of 1.9 months for paclitaxel (HR=0.36, p=0.0016).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.8.3-13"></a>

###### Post hoc analysis of overall survival within the control arm

> “In an analysis of OS in all patients randomized to the paclitaxel control arm (n=57), crossover patients who subsequently received tovecimig demonstrated a statistically significant improvement in median OS of 12.8 months compared to 6.1 months for non-crossover patients who received only paclitaxel (HR=0.54, p=0.04).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.8.3-14"></a>

###### Post hoc analysis of progression-free survival within the control arm

> “Another analysis of these same patients randomized to the paclitaxel control arm (n=57) demonstrated that the crossover patients initially progressed faster on paclitaxel monotherapy compared to the non-crossover patients, with a median PFS of 1.9 months versus 3.6 months (HR=2.31, p=0.007).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.8.3-15"></a>

###### Post hoc pooled overall survival of all participants who received tovecimig

> “For all patients treated with tovecimig, including both crossover patients and patients initially randomized to the tovecimig combination arm (n=142), the pooled median OS was 9.8 months. The median OS for patients randomized to the paclitaxel alone who did not crossover (n=26) was 6.1 months.”

Source: [Compass Therapeutics first quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/exh_991.htm)

<a id="topic-3.1.1.8.3-16"></a>

###### Crossover analyses in the peer-reviewed publication

> “Among the 31 patients who crossed over to the tovecimig plus paclitaxel arm, the ORR was 6.5%”
> “Median PFS improved from 1.9 months on paclitaxel alone (95% CI, 1.7–3.0) (PFS) to 3.5 months on tovecimig plus paclitaxel following crossover (95% CI, 1.7– 9.7) (post-progression PFS; HR, 0.40; 95% CI, 0.2–0.7”
> “This analysis should be interpreted with caution due to the lack of adjustment for intrapatient correlation.”
> “In an additional exploratory post hoc subgroup analysis, patients who received tovecimig plus paclitaxel at any time during the study (n=142) had a median OS of 9.9 months (95% CI, 7.5– 11.7).”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-3.1.1.8.3-17"></a>

###### Duration of response

> “Responses to tovecimig plus paclitaxel had a median DoR of 21.4 weeks (95% CI, 14.1–82.7) by KM estimation.”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-3.1.1.8.3-18"></a>

###### Disease control rate

> “DCR was significantly higher with tovecimig plus paclitaxel than with paclitaxel alone (62.2% vs 36.8%; P = .0018)”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Quality of life as a prespecified secondary endpoint

> “The secondary end points are progression free survival, duration of response, overall survival, disease control rate, safety and quality of life measured with EORTC QLQ-C30.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.1.8.4-2"></a>

###### Reported quality-of-life or patient-reported outcome results

> “PK and QoL analyses are ongoing and will be reported separately.”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Overall safety conclusion and most frequent events

> “Tovecimig was generally well tolerated and the safety profile was consistent with previously reported data from prior studies, with no new safety signals. The most commonly reported treatment emergent adverse events in the tovecimig combination arm were hypertension (69%) and fatigue (67%). The most common related treatment-emergent adverse events of Grade 3 or higher included hypertension (44%) and neutropenia (36%).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-3.1.1.8.5-2"></a>

###### Treatment-emergent adverse events reported in at least 20% of participants, n (%)

| Adverse event | Tovecimig plus paclitaxel (n=108), any grade | Tovecimig plus paclitaxel (n=108), grade 3 or higher | Paclitaxel (n=53), any grade | Paclitaxel (n=53), grade 3 or higher |
| --- | --- | --- | --- | --- |
| Hypertension | “75 (69)” | “56 (52)” | “10 (19)” | “3 (6)” |
| Fatigue | “72 (67)” | “16 (15)” | “24 (45)” | “3 (6)” |
| Neutropenia | “59 (55)” | “40 (37)” | “20 (38)” | “14 (26)” |
| Diarrhea | “51 (47)” | “6 (6)” | “15 (28)” | “1 (2)” |
| Anemia | “48 (44)” | “23 (21)” | “17 (32)” | “5 (9)” |
| Decreased appetite | “44 (41)” | “2 (2)” | “11 (21)” | “-” |
| Nausea | “43 (40)” | “2 (2)” | “17 (32)” | “-” |
| Proteinuria | “37 (34)” | “3 (3)” | “5 (9)” | “-” |
| Vomiting | “36 (33)” | “1 (1)” | “13 (25)” | “1 (2)” |
| Abdominal pain | “35 (32)” | “9 (8)” | “13 (25)” | “4 (8)” |
| Dyspnea | “32 (30)” | “5 (5)” | “13 (25)” | “-” |
| Epistaxis | “32 (30)” | “-” | “4 (8)” | “-” |
| Alopecia | “32 (30)” | “-” | “28 (53)” | “-” |
| Thrombocytopenia | “33 (31)” | “7 (7)” | “6 (11)” | “-” |
| Peripheral edema | “35 (32)” | “-” | “7 (13)” | “-” |
| Peripheral neuropathy | “29 (27)” | “2 (2)” | “13 (25)” | “1 (2)” |
| Constipation | “30 (28)” | “-” | “8 (15)” | “-” |
| Headache | “25 (23)” | “-” | “7 (13)” | “-” |
| Arthralgia | “25 (23)” | “-” | “6 (11)” | “-” |

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="topic-3.1.1.8.5-3"></a>

###### Consistency of the safety profile across data cuts

> “Safety profile generally consistent with previously reported data”

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="topic-3.1.1.8.5-4"></a>

###### Deaths, serious adverse events, and discontinuations due to adverse events

> “TEAEs leading to overall treatment discontinuation occurred in 27.8% and 11.3% of patients, respectively.”
> “Tovecimig required dose modifications in 78.7% of patients and was discontinued because of AEs in 30.6% of patients. TEAEs leading to death were reported in six patients (5.6%) in the combination arm and one patient (1.9%) in the paclitaxel-alone arm.”
> “two deaths were considered treatment-related, one involving sepsis and renal failure and one involving septic shock.”

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-3.1.1.8.5-5"></a>

###### Treatment-emergent adverse event categories, all-treated population, n (%)

| Category | Tovecimig plus paclitaxel (n=108) | Paclitaxel (n=53) |
| --- | --- | --- |
| Serious adverse event | “71 (65.7)” | “22 (41.5)” |
| Related serious adverse event | “43 (39.8)” | “10 (18.9)” |
| Grade 3 or higher treatment-emergent adverse event | “101 (93.5)” | “34 (64.2)” |
| Related grade 3 or higher treatment-emergent adverse event | “91 (84.3)” | “23 (43.4)” |
| Treatment-emergent adverse event leading to discontinuation of study treatment | “30 (27.8)” | “6 (11.3)” |
| Treatment-emergent adverse event leading to death | “6 (5.6)” | “1 (1.9)” |
| Treatment-emergent adverse event of special interest | “52 (48.1)” | “9 (17.0)” |

Source: [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

COMPANION-002 randomized 168 participants 2:1 and met its primary endpoint of objective response rate, reported first as 17.1% (19 of 111) versus 5.3% (3 of 57) with p=0.031 and updated in the final analysis to 18.0% (20 of 111) with p=0.0228 after one participant initially classified as non-complete response and non-progressive disease was adjudicated a partial response by blinded independent central review. The trial was powered to detect a 23% absolute difference in response rate with 90% power and a two-sided alpha of 0.05, so the observed difference of about 12 percentage points is smaller than the effect the sample size was planned around, and the planned sample size of approximately 150 was exceeded by the 168 actually randomized. The complete dataset was published in the Journal of Clinical Oncology in October 2026 and presented at the 2026 European Society for Medical Oncology Congress; the earlier results came from sponsor announcements and a corporate presentation filed with the U.S. Securities and Exchange Commission. The publication reports the post-crossover progression-free survival comparison with a hazard ratio of 0.40 and the pooled median overall survival of the 142 tovecimig-treated participants as 9.9 months, where the sponsor announcements reported 0.36 and 9.8 months.

Overall survival did not reach statistical significance. Median overall survival was 8.9 months with tovecimig plus paclitaxel versus 9.4 months in the control arm, hazard ratio 1.05 and p=0.78. The sponsor attributes this to crossover: 31 of 57 control participants (54%) crossed over after centrally confirmed progression, so 142 of 168 participants (85%) received tovecimig, and the control arm is not a tovecimig-naive comparator for survival. The prespecified rank-preserving structural failure time adjustment gave 8.9 versus 9.4 months with a hazard ratio of 1.13 and p=0.65, and the sponsor states that the assumptions of that method were not met and that its results here are largely uninterpretable. The crossover comparisons that show benefit, the 12.8 versus 6.1 month survival difference between crossover and non-crossover control participants and the pooled 9.8 month survival of all tovecimig-treated participants, are post hoc subset analyses of non-randomized groups; the same analysis showed crossover participants had progressed faster on paclitaxel alone, with median progression-free survival of 1.9 versus 3.6 months, indicating the two control subgroups differed.

The trial was conducted at 34 sites, all in the United States, and eligibility excluded participants who could receive an approved molecularly targeted therapy after first-line chemotherapy, so the results apply to the population without an actionable alteration rather than to all second-line biliary tract cancer. The registry record and the sponsor announcements describe different tovecimig schedules, day 1 and day 14 in the registry against days 1 and 15 in the press releases. The publication reports a median duration of response of 21.4 weeks, serious adverse events in 65.7% versus 41.5% of treated participants, discontinuation of study treatment for treatment-emergent adverse events in 27.8% versus 11.3%, and treatment-emergent adverse events leading to death in 5.6% versus 1.9%. The EORTC QLQ-C30 quality-of-life endpoint listed in the design publication has not been reported, and the publication states that quality-of-life analyses will be reported separately. The authors state that the study was not powered to evaluate efficacy within individual anatomical or molecular subgroups, and a post hoc two-stage crossover adjustment gave an overall survival hazard ratio of 0.85 (95% CI 0.59 to 1.26). Safety was reported for 108 and 53 participants rather than the 111 and 57 randomized, and grade 3 or higher hypertension occurred in 52% of the tovecimig arm against 6% of the control arm.

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943); [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm); [Compass Therapeutics first quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/exh_991.htm); [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm); [Compass Therapeutics third quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm); [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="heading-3.1.2"></a>

#### 3.1.2 ABL001-P1bC Phase 1b/2 Study of CTX-009 With Irinotecan or Paclitaxel

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registered objective

> “This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.”

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.1-2"></a>

###### Origin of the biliary tract cancer cohort

> “A phase Ib study conducted in South Korea, evaluated CTX-009 in combination with either irinotecan or paclitaxel in patients with metastatic or advanced solid tumors. Two out of three patients with cholangiocarcinoma who received CTX-009 in combination with paclitaxel achieved confirmed PRs. This observation in the phase Ib study led to the addition of a phase II cohort that enrolled patients with BTC who were treated in the second- or third-line setting.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

> “Encouraging results in the Phase 1b in BTC pts, including two durable Partial Responses (PRs) out of 3 pts, prompted the expansion of the study to include a Phase 2 cohort in which BTC pts are treated in 2L or 3L setting.”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and status: registry record

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2020-06-22” |
| Primary completion (actual) | “2024-01-08” |
| Study completion (actual) | “2025-01-09” |
| Enrollment (actual) | “41” |
| Recruitment status | “Terminated” |
| Reason stopped | “Change of Development Plan” |

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.2-2"></a>

###### Registered sites

> “This study has 4 locations”
> “South Korea”

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.2-3"></a>

###### Data cut-off and follow-up of the reported phase 2 analysis

> “Overall, 24 pts have been enrolled (IHCC: 9, EHCC: 3, GB: 7, AoV: 5) and as of the data cut-off date (August 12, 2022), the median follow-up duration was 11.8 months (m) (range: 1.6-16.4) and 3 pts remained on treatment.”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Registered design details

| Design feature | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.3-2"></a>

###### Phase 1b and phase 2 populations

> “Indication of phase 1b study is the advanced or metastatic solid tumors (including, but not limited to, colorectal cancer, gastric cancer, and ovarian cancer).”
> “Indication of phase 2 study is unresectable advanced, metastatic or recurrent biliary tract cancer (BTC) (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma).”

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.3-3"></a>

###### Single-arm phase 2 design as reported at the congress

> “This open-label, multi-center, single-arm Phase 2 study investigated pts with unresectable advanced, metastatic or recurrent BTC in advanced 2L or 3L setting.”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="topic-3.1.2.3-4"></a>

###### Simon two-stage adaptive design and the decision not to run the second stage

> “This Phase 2 trial utilized a Simon Two-Stage adaptive design where the criteria to advance to the second stage of the trial was three PRs observed in 21 evaluable patients.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria: registry record

| Criterion | Quoted registry text |
| --- | --- |
| Phase 2 diagnosis | “P2 only: Patients with histologically or cytologically confirmed unresectable advanced, metastatic, or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, ampullary carcinoma)” |
| Phase 2 prior therapy | “P2 only: Patients who have shown disease progress or recurrence of disease after receiving first-line or second-line systemic chemotherapy, including treatment with gemcitabine in combination with a platinum agent” |
| Age | “Patients aged 19 years or older” |
| Measurable disease | “At least one lesion measurable defined by response evaluation criteria in solid tumors (RECIST) version 1.1.” |
| Performance status | “ECOG performance status 0 or 1” |

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria: registry record

> “History of cardiac illness: New York Heart Association (NYHA) class ≥ II congestive heart failure (CHF), uncontrolled hypertension, hypertension crisis, pulmonary hypertension, myocardial infarction, uncontrolled arrhythmia, unstable angina”
> “Symptomatic or uncontrolled central nervous system (CNS) metastasis”
> “Administration of antiplatelets or anticoagulants within 2 weeks prior to screening”
> “Requiring continuous treatment with systemic NSAIDs or systemic corticosteroids”

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Phase 2 dosing regimen

> “Eligible pts were treated with CTX-009 (10 mg/kg IV biweekly) in combination with paclitaxel (80 mg/m2 IV on Day 1, 8, 15 q4-weekly).”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="topic-3.1.2.5-2"></a>

###### Registered interventions

| Intervention | Registry description |
| --- | --- |
| CTX-009 (ABL001) | “CTX-009 (ABL001) will be administered biweekly.” |
| Paclitaxel | “Paclitaxel will be administered weekly.” |
| Irinotecan | “Irinotecan will be administered biweekly.” |

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Registered primary outcome measures

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “P1b: Proportion of subjects with Dose-Limiting Toxicity (DLT)” | “Number of subjects who experience DLT events during 28 days after first administration of CTX-009 (ABL001) and Irinotecan/Paclitaxel, divided by the number of DLT-evaluable subjects” | “From Day 1 until disease progression or Day 28, whichever came first” |
| “P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTC” | “The proportion of subjects whose best overall response (BOR) is assessed to be complete response (CR) or partial response (PR) as per Independent Radiology Center's review” | “Up to approximately 24 months” |

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary and secondary objectives as reported at the congress

> “The primary objective was to assess the objective response rate (ORR) based on RECIST v1.1. Secondary endpoints included time to treatment failure (TTF), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="topic-3.1.2.6.1-3"></a>

###### Response-rate threshold used to size the study

> “This Phase 2 trial utilized a Simon Two-Stage adaptive design where the criteria to advance to the second stage of the trial was three PRs observed in 21 evaluable patients.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Total enrollment across both phases

> “41”

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants analyzed in the phase 2 biliary tract cancer cohort

> “A total of 24 patients were enrolled: nine (37%) with intrahepatic cholangiocarcinoma, three (13%) with extrahepatic cholangiocarcinoma, seven (29%) with gallbladder cancer and five (21%) with ampullary carcinoma.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants analyzed in the phase 1b cholangiocarcinoma subset

> “In the Phase 1b study, there were four patients enrolled with cholangiocarcinoma. Two of these four patients had deep, durable, and confirmed responses.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Basis of the reported response assessment

> “There were 9 confirmed PRs by investigator’s assessment and ORR was 37.5% (95% CI: 18.8-59.4; 2L: 63.6%, 3L: 15.4%).”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="topic-3.1.2.7.2-2"></a>

###### Formal definition of the efficacy and safety analysis sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participants remaining on treatment at the data cut-off

> “Overall, 24 pts have been enrolled (IHCC: 9, EHCC: 3, GB: 7, AoV: 5) and as of the data cut-off date (August 12, 2022), the median follow-up duration was 11.8 months (m) (range: 1.6-16.4) and 3 pts remained on treatment.”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="topic-3.1.2.8.1-2"></a>

###### Discontinuation due to adverse events

> “Six pts (25.0%) experienced treatment-emergent AEs (confusional state, pulmonary embolism, blood creatinine increased, pneumonia, biliary fistula, and large intestine perforation) that led to discontinuation of the study treatment.”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Line of therapy and anatomic subtype

> “11 pts were treated in 2L and 13 pts treated in 3L.”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

> “A total of 24 patients were enrolled: nine (37%) with intrahepatic cholangiocarcinoma, three (13%) with extrahepatic cholangiocarcinoma, seven (29%) with gallbladder cancer and five (21%) with ampullary carcinoma.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-3.1.2.8.2-2"></a>

###### Age, sex, and performance status at baseline

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Response and survival outcomes as reported at the congress

> “There were 9 confirmed PRs by investigator’s assessment and ORR was 37.5% (95% CI: 18.8-59.4; 2L: 63.6%, 3L: 15.4%). Median DOR and PFS were 9.4 m (95% CI: 3.5–NE) and 9.4 m (95% CI: 5.4-11.1), respectively. Median TTF was 5.9 m (95% CI: 3.9-9.8) and median OS has not been reached (95% CI: 11.0–NE); the OS rate at 12 m was 53.0% (95% CI: 29.8–71.7).”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="topic-3.1.2.8.3-2"></a>

###### Response and survival outcomes as summarized in the trial design publication

> “The primary end point of the phase II study was overall response rate (ORR) and the ORR was 37.5% (n = 9/24 patients). Among 11 patients treated in the second-line, the ORR was 63.6% (n = 7/11) versus 15% (n = 2/13) among patients treated in the third-line setting. The median duration of response was 6.9 months, and responses were seen in patients with all anatomic subtypes of BTC, including ampullary cancer. The median progression-free survival was 9.4 months and the survival rate at 1 year was 53%.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Treatment-related adverse events as reported at the congress

> “Treatment-related adverse events (TRAEs) of any grade were reported in 100% of pts and TRAEs of ≥ grade 3 were reported in 75% of pts (including one grade 5 pneumonia). The most frequent TRAEs of ≥ grade 3 were neutropenia (50.0%), hypertension (16.7%), anemia (12.5%), and thrombocytopenia (8.3%).”

Source: [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)

<a id="topic-3.1.2.8.5-2"></a>

###### Treatment-emergent adverse events regardless of relationship, as reported by the sponsor

> “Of the 24 patients enrolled in the trial, all patients had at least one treatment emergent adverse event (“TEAE”). Grade 3 or greater TEAEs were reported in 95.8% of patients regardless of the relationship to tovecimig or paclitaxel, including decreased neutrophil count (83.3%), hypertension (16.7%), anemia (20.8%), and decreased platelet count (12.5%).”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### Adverse events of special interest

> “Grade 3 or greater adverse events that were designated to be of special interest (“AESIs”) by the trial investigators were hemoptysis or hemorrhage (12.5%) and GI or tumor perforation (8.3%), with 0% for pulmonary hypertension, wound healing complication and cardiac failure.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The phase 2 biliary tract cancer cohort was single-arm, open-label, and enrolled 24 participants at four sites, all in South Korea, so its 37.5% response rate has no concurrent control and was not estimated in a United States population. Responses were assessed by investigator review in the reported analysis rather than by the independent radiology review named as the registered primary outcome measure. Participants had received one or two prior systemic therapies, and the response rate differed markedly by line of therapy, 63.6% in the second line against 15.4% in the third line, so the estimate depends on the mix of lines enrolled. Two sources report different durations of response for the same cohort, a median of 9.4 months in the congress abstract and 6.9 months in the trial design publication, and median overall survival had not been reached at the August 12, 2022 data cut-off with a median follow-up of 11.8 months. Toxicity was frequent: treatment-related adverse events of grade 3 or higher were reported in 75% of participants, including one grade 5 pneumonia, and six participants (25.0%) discontinued because of a treatment-emergent adverse event. The study was terminated for a change of development plan, and the second stage of the Simon two-stage design was not conducted after the sponsor agreed with the U.S. Food and Drug Administration to move directly to a randomized trial, so the cohort was never expanded to the planned size. No baseline demographic table, quality-of-life outcome, or peer-reviewed full report of the cohort has been published.

Source: [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033); [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540); [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.3"></a>

#### 3.1.3 COMPANION-003

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registered objective

> “This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer.”

Source: [ClinicalTrials.gov NCT05513742](https://clinicaltrials.gov/study/NCT05513742)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates and status: registry record

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2022-12-08” |
| Primary completion (actual) | “2025-05-15” |
| Study completion (actual) | “2025-05-15” |
| Enrollment (actual) | “49” |
| Results first posted | “2026-07-28” |

Source: [ClinicalTrials.gov NCT05513742](https://clinicaltrials.gov/study/NCT05513742); [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.2-2"></a>

###### Region of enrollment

> “United States 49”

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.2-3"></a>

###### Presentation of the results

> “Tovecimig’s Phase 2 monotherapy data in patients with advanced, metastatic CRC treated in the third- and fourth-line settings will be presented at the 2026 ASCO GI Cancers Symposium in San Francisco on Saturday, January 9, 2026.”

Source: [Compass Therapeutics corporate update (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/exh_991.htm)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Registered design details

| Design feature | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.3-2"></a>

###### Two-stage enrollment plan

> “A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.”

Source: [ClinicalTrials.gov NCT05513742](https://clinicaltrials.gov/study/NCT05513742)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Line of therapy

> “A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens”

Source: [ClinicalTrials.gov NCT05513742](https://clinicaltrials.gov/study/NCT05513742)

<a id="topic-3.1.3.4-2"></a>

###### Prior bevacizumab exposure of the enrolled population

> “Tovecimig demonstrated monotherapy activity, with an overall response rate of 5% (2 out of 40 patients), in heavily pre-treated patients, all of whom had previously been treated with bevacizumab (~51% had been treated with two or more prior rounds of bevacizumab).”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Dose and schedule

> “10 mg/kg body weight by IV infusion over 1 hour every 2 weeks”

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

> “IV infusion administered on day 1 and 15 of every 28-day cycle”

Source: [ClinicalTrials.gov NCT05513742](https://clinicaltrials.gov/study/NCT05513742)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Overall Response Rate as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Registered primary outcome measure

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Overall Response Rate” | “Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: >=30% decrease in the sum of the longest diameter of target lesions.” | “From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)” |

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.6.1-2"></a>

###### Response-rate benchmark used to interpret the endpoint

> “Tovecimig’s activity in this patient population differentiates it from other anti-VEGF agents, which have shown 1.0-1.5% response rates in this patient population.”

Source: [Compass Therapeutics corporate update (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/exh_991.htm)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned and actual enrollment and the stage 1 stopping decision

> “The protocol required enrolment of approximately 40 (minimum of 37) response evaluable participants. A total of 49 participants were enrolled in Stage 1, yielding 40 response evaluable participants. The study results did not meet the protocol-defined criterion for progression to Stage 2, and thus enrollment ended after Stage 1.”

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Population analyzed for the posted outcome measures

> “Overall Number of Baseline Participants 49”

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.7.2-2"></a>

###### Population analyzed for duration of response

> “Calculated for patients who had confirmed complete or partial response”

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Reasons for not completing the study

| Disposition | Participants |
| --- | --- |
| Started | “49” |
| Completed | “0” |
| Not completed | “49” |
| Death | “34” |
| Lost to follow-up | “1” |
| Withdrawal by subject | “7” |
| Study termination by sponsor | “7” |

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Age and region

| Characteristic | CTX-009 10 mg/kg (n=49) |
| --- | --- |
| Mean age, years (standard deviation) | “58.6(11.54)” |
| Region of enrollment | “United States 49” |

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Response and survival as reported by the sponsor in the response-evaluable population

> “Tovecimig demonstrated monotherapy activity, with an overall response rate of 5% (2 out of 40 patients), in heavily pre-treated patients, all of whom had previously been treated with bevacizumab (~51% had been treated with two or more prior rounds of bevacizumab). Tovecimig also demonstrated a DCR of 68% (27 out of 40), median PFS of 3.9 months and median OS of 10.2 months.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-3.1.3.8.3-2"></a>

###### Posted time-to-event outcomes in all treated participants

| Outcome measure | Median | Interquartile range | Participants analyzed |
| --- | --- | --- | --- |
| Duration of response, weeks | “14.4” | “(13.3 to 15.4)” | “2” |
| Progression-free survival, months | “3.9” | “(1.8 to 5.8)” | “49” |
| Overall survival, months | “10.2” | “(5.3 to 17.8)” | “49” |

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.8.3-3"></a>

###### Association between DLL4 expression and outcome

> “Although DLL4 expression on colorectal tumors is a negative prognostic factor, the data indicate that patients with DLL4-positive tumors did better with tovecimig therapy than patients with DLL4-negative tumors.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Overall adverse event rates

| Category | Affected / at risk (%) |
| --- | --- |
| All-cause mortality | “34/49 (69.39%)” |
| Serious adverse events | “14/49 (28.57%)” |
| Other, non-serious adverse events | “47/49 (95.92%)” |

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.8.5-2"></a>

###### Most frequent non-serious adverse events

| Adverse event | Affected / at risk (%) |
| --- | --- |
| Hypertension | “22/49 (44.90%)” |
| Proteinuria | “18/49 (36.73%)” |
| Nausea | “14/49 (28.57%)” |
| Fatigue | “13/49 (26.53%)” |
| Weight decreased | “11/49 (22.45%)” |
| Headache | “10/49 (20.41%)” |
| Cardiac failure | “9/49 (18.37%)” |
| Diarrhoea | “8/49 (16.33%)” |
| Decreased appetite | “8/49 (16.33%)” |

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.8.5-3"></a>

###### Nature of the reported cardiac failure events

> “due to asymptomatic B-type natriuretic peptide (BNP) elevation, Grade 1”

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)

<a id="topic-3.1.3.8.5-4"></a>

###### Sponsor characterization of the safety profile

> “Tovecimig’s safety profile was generally consistent with prior studies with hypertension as the most common treatment-emergent adverse event, all of which occurred in patients with a prior history of hypertension.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

COMPANION-003 studied tovecimig as monotherapy in metastatic colorectal cancer, not in biliary tract cancer, so it informs the safety profile and the DLL4 biomarker hypothesis rather than the indication. It was open-label and single-arm, enrolled 49 participants at sites in the United States only, and stopped after stage 1 because the protocol-defined criterion for progression to stage 2 was not met. Only 2 of 40 response-evaluable participants responded, and duration of response was estimated from those 2 participants, so the 14.4 week median is not a stable estimate. The sponsor reports response and disease control against a denominator of 40 response-evaluable participants while the registry posts outcomes against all 49 enrolled, so the two sets of figures are not interchangeable. The registry record specifies RECIST version 1.0 for the response definitions although the drug program otherwise uses RECIST version 1.1. No participant completed the study, 34 of 49 participants died, 7 withdrew, and 7 ended participation when the sponsor terminated the study, so follow-up was truncated. The comparison with anti-VEGF agents showing 1.0% to 1.5% response rates is a cross-trial comparison, and the statement that participants with DLL4-positive tumors did better is an unadjusted subgroup observation. Quality-of-life outcomes were not collected, and the results are available from the registry and sponsor filings rather than a peer-reviewed publication.

Source: [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results); [ClinicalTrials.gov NCT05513742](https://clinicaltrials.gov/study/NCT05513742); [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm); [Compass Therapeutics corporate update (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/exh_991.htm)

<a id="heading-3.1.4"></a>

#### 3.1.4 2024-0279 First-line CTX-009 With Gemcitabine, Cisplatin, and Durvalumab

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registered objective

> “To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.”

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="topic-3.1.4.1-2"></a>

###### Primary and secondary objectives

> “Assess tolerability/safety of this combination and determine the maximum tolerated dose (MTD) of CTX-009.”
> “Assess 6 month progression-free survival to the combination therapy according to RECIST 1.1”

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study dates, status, and site: registry record

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2025-01-22” |
| Primary completion (estimated) | “2027-05-01” |
| Enrollment (estimated) | “50” |
| Recruitment status | “Recruiting” |
| Last update posted | “2026-09-09” |

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="topic-3.1.4.2-2"></a>

###### Sponsoring institution and site

> “M.D. Anderson Cancer Center”
> “Houston, Texas, United States”

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Safety lead-in followed by expansion

> “Safety Lead-in: CTX-009+ Durvalumab+Gemcitabine+cisplatin”
> “Expansion: CTX-009+ Durvalumab+Gemcitabine+cisplatin”

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="topic-3.1.4.3-2"></a>

###### Sponsor description of the investigator-sponsored trial

> “The investigator sponsored trial (IST) of tovecimig in combination with the current first-line, standard-of-care regimen of gemcitabine, cisplatin, and durvalumab in patients with BTC (NCT06548412) is ongoing with expansion to additional sites expected.”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Key inclusion criteria: registry record

| Criterion | Quoted registry text |
| --- | --- |
| Age | “Age ≥ 18 years.” |
| Diagnosis and prior therapy | “Histologically or cytologically confirmed (outside pathology reports will be accepted) unresectable advanced, metastatic, or recurrent BTC at the time of enrollment that has not been previously treated in the metastatic setting.” |
| Performance status | “ECOG performance status ≤2” |

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Registered interventions

> “Given by IV”

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="topic-3.1.4.5-2"></a>

###### Doses and schedules of each agent

No evidence found.

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Incidence of Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary outcome measure

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Safety and Adverse Events (AEs)” | “Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0” | “Through study completion; an average of 1 year” |

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="topic-3.1.4.6.1-2"></a>

###### Justification of the primary endpoint

Not applicable.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment

> “50”

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

This is an investigator-sponsored phase 1/2 trial at a single institution with an estimated enrollment of 50 participants and no randomization or comparator arm. Its primary outcome measures are the incidence of adverse events and 6-month progression-free survival, so it is designed to establish tolerability and a maximum tolerated dose of CTX-009 added to gemcitabine, cisplatin, and durvalumab rather than to demonstrate efficacy. The population is first-line and previously untreated in the metastatic setting, which is a different population from the second-line population of COMPANION-002. Estimated primary completion is May 1, 2027, and no results had been posted or presented as of the September 9, 2026 registry update. The registry record does not state the doses or schedules of the four agents.

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="heading-3.1.5"></a>

#### 3.1.5 Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Registered objective

> “This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).”

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study dates, status, and site: registry record

| Milestone | Registry record |
| --- | --- |
| Study start (estimated) | “2026-08-31” |
| Primary completion (estimated) | “2030-08-31” |
| Enrollment (estimated) | “25” |
| Recruitment status | “Not yet recruiting” |
| Last update posted | “2026-06-23” |

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="topic-3.1.5.2-2"></a>

###### Sponsoring institution and site

> “Washington University School of Medicine”
> “St Louis, Missouri, United States”

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Single-group open-label phase 2 design

> “A Phase 2 Clinical Trial of Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer”

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="topic-3.1.5.3-2"></a>

###### Sponsor description of the investigator-sponsored trial

> “Additional ISTs of tovecimig have been initiated, including a study of tovecimig plus FOLFIRI in patients with colorectal cancer in the second line setting (NCT07662031); and a novel-novel combination study of tovecimig plus CTX-471 in patients with glioblastoma in the second line setting (NCT07392957).”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Key inclusion criteria: registry record

| Criterion | Quoted registry text |
| --- | --- |
| Diagnosis | “Histologically or cytologically confirmed CRC.” |
| Prior therapy | “Patient must have advanced or metastatic disease, and have progressed on one line of standard of care therapy in the advanced/metastatic setting” |
| Measurable disease | “Measurable disease per RECIST 1.1.” |
| Age | “At least 18 years of age.” |
| Performance status | “ECOG performance status ≤ 2” |

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Registered regimen

> “Treatment will be administered in 28-day cycles. On Day 1 and 15 of each cycle, patients will receive Tovecimig followed by the FOLFIRI regimen.”

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Overall Response Rate as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Registered primary outcome measure

| Outcome measure | Time frame |
| --- | --- |
| “Overall Response Rate (ORR)” | “Start of treatment to completion of treatment (estimated time up to 12 months)” |

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="topic-3.1.5.6.1-2"></a>

###### Justification of the primary endpoint

Not applicable.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned enrollment

> “25”

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### Registered performance-status outcome measure

> “Change in quality of life as measured by Eastern Cooperative Oncology Group (ECOG) performance status”

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="topic-3.1.5.8.4-2"></a>

###### Reported quality-of-life results

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

This is an investigator-sponsored, open-label, single-group phase 2 trial at one institution with an estimated enrollment of 25 participants, in metastatic colorectal cancer rather than biliary tract cancer. As of the June 23, 2026 registry update it was not yet recruiting, with an estimated start of August 31, 2026 and estimated primary completion of August 31, 2030, so no results exist. The single-group design without a comparator means the primary outcome of overall response rate cannot be attributed to the addition of tovecimig to FOLFIRI, and the planned quality-of-life measure is change in Eastern Cooperative Oncology Group performance status rather than a patient-reported instrument.

Source: [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)

<a id="heading-3.1.6"></a>

#### 3.1.6 CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Registered objective

> “This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma.”

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="topic-3.1.6.1-2"></a>

###### Mechanistic hypothesis

> “CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab, CTX-471 restores local immune reactivity through activation of costimulatory immune mediators.”

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study dates, status, and site: registry record

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2026-06-16” |
| Primary completion (estimated) | “2029-06-30” |
| Enrollment (estimated) | “54” |
| Recruitment status | “Recruiting” |
| Last update posted | “2026-06-22” |

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="topic-3.1.6.2-2"></a>

###### Sponsoring institution and site

> “Washington University School of Medicine”
> “St Louis, Missouri, United States”

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Sequential enrollment of the monotherapy and combination arms

> “After completion of enrollment to Arm 1 (phase IB and phase II), enrollment will open to Arm 2.”

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Key inclusion criteria: registry record

| Criterion | Quoted registry text |
| --- | --- |
| Diagnosis | “Histologically or radiographically confirmed recurrent CNS WHO grade 4 IDH wild-type glioma following standard of care treatment including radiation, chemotherapy, and/or tumor-treating fields. No more than 2 recurrences are allowed.” |
| Age | “At least 18 years of age.” |
| Performance status | “KPS performance status ≥ 60%” |

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Registered dosing of CTX-009

> “CTX-009 will be given intravenously at the assigned dose level on an outpatient basis every 2 weeks of a 28-day cycle.”

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Overall Survival Rate at 12 Months as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Registered primary outcome measures

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Phase IB Arm 1: Recommended Phase 2 Dose (RP2D)” | “RP2D will be determined from the phase IB portion of Arm 1 by assessing tolerability.” | “Start of treatment through completion of cycle 1 (each cycle is 28 days)” |
| “Phase II Arm 1: Overall survival rate at 12 months (OS12)” | “Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.” | “12 months” |
| “Phase II Arm 2: Overall survival rate at 12 months (OS12)” | “Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.” | “12 months” |

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="topic-3.1.6.6.1-2"></a>

###### Justification of the primary endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Planned enrollment

> “54”

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

No evidence found.

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

This is an investigator-sponsored phase 1b/2 trial at one institution in recurrent glioblastoma, not biliary tract cancer, with an estimated enrollment of 54 participants. The two arms enroll sequentially rather than concurrently, so the monotherapy and combination arms are not randomized against each other. The trial began on June 16, 2026 with estimated primary completion on June 30, 2029, and no results had been posted as of the June 22, 2026 registry update. The phase 2 primary outcome is the 12-month overall survival rate in each arm without a control group, so it will be interpreted against external benchmarks.

Source: [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)

<a id="heading-3.1.7"></a>

#### 3.1.7 NOV150101-101 First-in-Human Phase 1 Dose Escalation and Expansion

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Registered objective

> “The purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NOV1501 (ABL001).”

Source: [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783)

<a id="topic-3.1.7.1-2"></a>

###### Objective as reported at the congress

> “A phase 1, multicenter, open-label and first-in-human study was conducted to evaluate the safety and tolerability of ABL001 (CTX-009) in patients with advanced solid tumors.”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Study dates and status: registry record

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2017-09-18” |
| Primary completion (actual) | “2021-03-02” |
| Study completion (actual) | “2021-03-02” |
| Enrollment (actual) | “45” |
| Recruitment status | “Completed” |

Source: [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783)

<a id="topic-3.1.7.2-2"></a>

###### Study sites

> “This study was conducted at three different sites in the Republic of Korea (Seoul National University Hospital Bundang, Samsung Medical Center, and Asan Medical center) and was approved by the Institutional Review Board (IRB) of Seoul National University Hospital Bundang, the IRB of Samsung Medical Center, and the IRB of Asan Medical Center.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Registered design details

| Design feature | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 1” |

Source: [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783)

<a id="topic-3.1.7.3-2"></a>

###### Dose escalation and expansion structure

> “The dose escalation phase had 9 dose cohorts from 0.3 to 17.5 mg/kg (IV every 2 weeks), using a traditional 3+3 design. The study was expanded at dose levels of 7.5, 10, 12.5 and 15 mg/kg. Archived tumor tissue samples were collected to assess DLL4 expression levels using an immunohistochemistry (IHC) method.”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="topic-3.1.7.3-3"></a>

###### Dose levels, starting dose, and administration schedule

> “The initial dose of 0.3 mg/kg was determined based on the no observed adverse effect level (NOAEL) 10 mg/kg in the monkey model, converted to human equivalent dose with the safety factor of 10.”
> “After confirming safety in the dose escalation cohort, additional patients were recruited in 7.5, 10, 12.5, and 15 mg/kg dose groups, which were the target dose levels to show clinically meaningful efficacy based on the results of the preclinical study (data on file).”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Key inclusion criteria: registry record

| Criterion | Quoted registry text |
| --- | --- |
| Age and diagnosis | “≥19 year old patients with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors” |
| Measurable disease | “Lesions measured by tumor markers or by CT/MRI must be evaluable based on response evaluation criteria in solid tumors (RECIST) version 1.1.” |
| Life expectancy | “Life expectancy ≥12 weeks” |
| Performance status | “ECOG performance status ≤2” |

Source: [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783)

<a id="topic-3.1.7.4-2"></a>

###### Key selection criteria as reported at the congress

> “Key selection criteria included: age ≥19 years, metastatic or unresectable advanced solid tumors, ECOG ≤2, and adequate hematologic, hepatic and renal function.”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="topic-3.1.7.4-3"></a>

###### Exclusion of prior anti-DLL4 therapy and clinically significant cardiovascular disease

> “Patients who had clinically significant cardiovascular disease, including pulmonary hypertension and myocardial infarction, hypersensitivity to humanized/human mAb, or who previously received anti‐DLL4 antibody were excluded.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Route, infusion duration, and dosing interval

> “Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h. ABL001/CTX‐009 was administered in a 2‐week cycle, with the exception of the second dose, which had a 3‐week interval. Administration continued until unacceptable toxicity or disease progression was identified according to RECIST version 1.1.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-3.1.7.5-2"></a>

###### Registered intervention

> “VEGF/DLL4 targeting bispecific antibody”

Source: [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Dose-limiting Toxicity as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Registered primary outcome measure

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)” | “The maximum tolerated dose/maximum administered dose will be determined by the number of participant experiencing DLTs. The safety profile will be assessed through number of participants experiencing AEs, SAEs, abnormal laboratory parameters, vital signs and electrocardiogram (ECG) results.” | “From time of 1st administration of ABL001 until day 21.” |

Source: [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783)

<a id="topic-3.1.7.6.1-2"></a>

###### Justification of the primary endpoint

Not applicable.

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Participants enrolled by study part

> “A total of 45 patients (31 patients in the dose escalation phase and 14 patients in the dose expansion phase) were enrolled in the study.”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="topic-3.1.7.7.1-2"></a>

###### Participants contributing to the population pharmacokinetic analysis

> “From the dose escalation cohort, a total of 712 PK samples from 31 patients were included for population PK model development (0.3 mg/kg = 4, 1 mg/kg = 4, 2.5 mg/kg = 3, 5 mg/kg = 4, 7.5 mg/kg = 3, 10 mg/kg = 3, 12 mg/kg = 3, 15 mg/kg = 4, and 17.5 mg/kg = 3).”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Response-evaluable population

> “Of the 39 evaluable patients, there were 4 partial responses (PRs) and 3 of those responses were confirmed by RECIST.”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

> “There were four partial responses (PRs) observed among 40 patients evaluable for response; three of the four responses were confirmed by RECIST.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Prior therapy, performance status, and tumor types

> “The patients were heavily pretreated and received a median of 4 lines of prior therapies. 86.7% of the patients were ECOG 1. Gastric cancer (n=19) and colorectal cancer (n=18) were the most common tumors.”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="topic-3.1.7.8.2-2"></a>

###### Age and body weight in the dose escalation cohort

| Characteristic | Dose escalation cohort (N = 31) |
| --- | --- |
| Mean age, years (standard deviation) | “53.5 (12.4)” |
| Age range, years | “25, 81” |
| Mean weight, kg (standard deviation) | “64.2 (16.4)” |

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-3.1.7.8.2-3"></a>

###### Biliary tract cancer subset at baseline

No evidence found.

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Responses, dose levels at which they occurred, and DLL4 expression

> “Of the 39 evaluable patients, there were 4 partial responses (PRs) and 3 of those responses were confirmed by RECIST. Responses began to appear at the 10 mg/kg dose level. The 3 confirmed partial responses included 2 colorectal cancer patients at 10 mg/kg and 1 gastric cancer patient at 12.5 mg/kg. All 3 patients with PRs exhibited high DLL4 expression by IHC on archived tumor tissue samples. The unconfirmed PR was in a patient with gastric cancer dosed at 15 mg/kg who was also DLL4 IHC positive.”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="topic-3.1.7.8.3-2"></a>

###### Response and disease control at the recommended phase 2 doses

> “The recommended Phase 2 doses (RP2Ds) were determined to be 10 mg/kg and 12.5 mg/kg and the Overall Response Rate (ORR) at the RP2D was 18.8% (3/16) and the Disease Control Rate (DCR) was 62.5% (11/16).”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="topic-3.1.7.8.3-3"></a>

###### Efficacy in the biliary tract cancer subset of the phase 1 monotherapy study

No evidence found.

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Dose-limiting toxicities and treatment-emergent adverse events

> “No dose limiting toxicities (DLTs) were observed. The most common Treatment-Emergent Adverse Events (TEAEs) reported in ≥10% patients were hypertension (37.8%), headache (22.2%), anemia (13.3%), asthenia (13.3%) and fatigue (11.1%). Grade 3 or greater TEAEs reported in ≥5% patients were hypertension (15.6%) and anemia (6.7%). The most common Treatment Related Adverse Events (TRAEs) reported in ≥10% patients were hypertension (37.8%) and headache (15.6%).”

Source: [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)

<a id="topic-3.1.7.8.5-2"></a>

###### Tolerability across the dose range

> “ABL001/CTX‐009 showed favorable tolerability in the dose range from 0.3 to 17.5 mg/kg in this first‐in‐human study in patients with advanced solid tumors.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

The first-in-human study was open-label, single-arm, and enrolled 45 participants at sites in South Korea only, so it supports dose selection rather than efficacy. No maximum tolerated dose was reached because no dose-limiting toxicities were observed across nine dose levels from 0.3 to 17.5 mg/kg, so the recommended phase 2 doses of 10 mg/kg and 12.5 mg/kg rest on activity and pharmacokinetics rather than on toxicity. Participants were heavily pretreated, with a median of four prior lines, and the tumor types enrolled were predominantly gastric (n=19) and colorectal (n=18) cancer; no biliary tract cancer subset result is reported, so the study provides no direct evidence for the indication. Two sources give different response-evaluable denominators for the same analysis, 39 in the congress abstract and 40 in the trial design publication, and the response rate of 18.8% at the recommended phase 2 doses is based on 3 responses among 16 participants. Only three confirmed partial responses occurred, all in participants whose archived tumor tissue showed high DLL4 expression, a finding from a small biomarker subset that was not prospectively tested. The study has been reported only as a congress abstract and, for pharmacokinetics, as a modeling paper using data from 31 dose escalation participants; no full clinical report has been published, and participant disposition and quality-of-life outcomes are not available.

Source: [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783); [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03); [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/); [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

## Related pages
- [Tovecimig (CTX-009): Second-line advanced biliary tract cancer](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Terms and abbreviations](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/terms-and-abbreviations.md)
- [Tovecimig (CTX-009): Second-line advanced biliary tract cancer](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/executive-summary.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Product information and disease description](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/product-information-and-disease-description.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Economic information and modeling report](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/economics.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: References](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/references) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/references.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: formulary monograph](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: drug evaluation](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph/oregon.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: prevalence by geography](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/prevalence.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/cost-effectiveness-analyses.md)
